羧甲基纤维素 (CMC)是使用范围最广、用量最大的纤维素材料。CMC无毒无味、性能稳定且易溶于水，多用于制作创面敷料以防止创面感染、控制创面渗液以及促进创面愈合。由于人体内缺乏纤维素消化酶 (纤维素酶)，因此作为植入材料时，纤维素材料能够抵抗降解，长时间保持结构稳定。该特性使得纤维素材料能够用于如防止腹部术后腹膜粘连、减少肠梗阻发生等。
CMCMA是由羧甲基纤维素 (CMC)经甲基丙烯酸酐 (MA)修饰得到的、具有光敏特性的高分子材料，可与蓝光或紫外光引发剂配合使用，在蓝光或紫外光辐照下交联固化。该高分子生物相容性优异、用作植入材料结构稳定、固化简单，可用于药物缓释、组织工程器官构建、创伤敷料、防黏连保护层等领域。
产品规格
| 组分 | 外观 | 规格 | 备注 | | CMCMA | 白色或类白色粉末颗粒 | 1 g/瓶、5 g/瓶 | 避光保存 |
|
使用建议
1、CMCMA可与邻硝基苄醇化高分子，如PEGNB、HANB、GelNB联合使用。二者由光引发剂LAP、NAP光照引发聚合并交联，仅需数秒即可获得高强度水凝胶材料。
2、CMCMA可与甲基丙烯基修饰的高分子，如HAMA、GelMA、CSMA、ChMA以及丙烯基修饰的高分子，如F127DA联合使用，由光引发剂光照引发聚合，构建不同理化性能的水凝胶材料。
3、CMCMA单独使用，由光引发剂光照引发聚合并交联。
配制方法
1、配制光引发剂标准液：取一定质量的NAP或LAP配制成浓度为0.1 wt%-0.25 wt%范围内的溶液，2-8 ℃避光保存；
2、取所需质量的CMCMA放入离心管，并取所需体积的引发剂标准溶液加入到上述离心管中；
3、将上述样品于室温下避光搅拌或于摇床振荡，直至完全溶解。样品如在溶液中结块，可先用药匙碾碎；若样品溶解速度偏慢，可置于50-60℃环境加热搅拌助溶。
注意事项
1、CMCMA的标记率 (取代度)越高，配制的浓度越高，固化后形成的凝胶模量越大，固化时间越短。
2、CMCMA的分子量越高，固化后形成的凝胶韧性越好，不易破碎。
3、CMCMA的分子量越高，配制成的溶液粘度越大。分子量为300 kDa的CMCMA，建议使用浓度不超过3 wt%；分子量为90 kDa的CMCMA，建议使用浓度不超过6 wt%。
4、光引发剂标准液浓度越高，CMCMA溶液固化速度越快，固化后形成的凝胶越脆。
产品应用
1. 药物缓释、生物打印、组织工程器官构建、创伤敷料、防黏连保护层等。
2. 软骨细胞分化：构建载细胞水凝胶促进离体软骨细胞的再分化。
灭菌方式
1、过滤灭菌 (建议)：使用0.22 μm无菌针头过滤器过滤溶液灭菌。此方法仅限于低浓度溶液使用，如溶液浓度较高时，请选用巴氏灭菌或湿热灭菌法；
2、巴氏灭菌：将溶液加热到80 ℃，保持30 min；再迅速转移至冰水混合物中冷却至常温。共循环上述操作三次；
3、热灭菌：将溶液于高温高压灭菌锅内，121 ℃下灭菌8 min，手动放气后，将溶液迅速转移至冰水混合物中冷却至常温。需注意，高温条件会导致凝胶性能下降，因此使用该方法灭菌时应严格遵守上述操作步骤。
注：无菌溶液可以2-8 ℃避光暂存，建议7天内使用；非无菌溶液可以2-8 ℃避光暂存，建议48小时内使用。
产品优势
1、批次稳定：采用标准化的生产工艺，保证不同批次的CMCMA在成分、理化特性和生物学方面具有高度的重复性和可控性。
2、超高纯度：采用独特的生产工艺，有效地去除甲基丙烯酸小分子和工艺杂质，实现超低杂质水平，保证CMCMA在生物医学应用的安全性。
3、可靠的安全性：每批产品均经过严格的标准化的检验后放行，保证CMCMA在生物医学应用的安全性。
4、高稳定性：参照《无源植入性医疗器械稳定性研究指导原则》，经过实时稳定性和加速稳定性试验证明：CMCMA产品在标示贮存条件下质量稳定。
Carboxymethyl cellulose (CMC) is the most widely used and most abundant cellulosic material. CMC is non-toxic, odorless, stable in performance, and readily soluble in water. It is commonly used in the production of wound dressings to prevent wound infection, control exudate, and promote wound healing. Since the human body lacks cellulose-digesting enzymes (cellulases), cellulosic materials can resist degradation and maintain structural stability for a long time when used as implant materials. This property enables cellulosic materials to be applied in preventing postoperative peritoneal adhesions, reducing the incidence of intestinal obstruction, and other applications.
CMCMA is a photosensitive polymer material obtained by modifying carboxymethyl cellulose (CMC) with methacrylic anhydride (MA). It can be used in combination with blue light or UV photoinitiators to undergo cross-linking and curing under blue light or UV irradiation. This polymer exhibits excellent biocompatibility, structural stability as an implant material, and simple curing properties, making it suitable for applications such as controlled drug release, tissue engineering organ construction, wound dressings, and anti-adhesion barrier layers.
Product Specifications
| Component | Appearance | Specification | Remarks | | CMCMA | White or off-white powder or granules | 1 g/vial, 5 g/vial | Store in the dark.
|
|
Usage Recommendations
1. CMCMA can be used in combination with o-nitrobenzyl alcohol-modified polymers, such as PEGNB, HANB, and GelNB. Both can be polymerized and cross-linked upon illumination with photoinitiators LAP or NAP, yielding high-strength hydrogel materials in just a few seconds.
2. CMCMA can be used in combination with methacryl-modified polymers (e.g., HAMA, GelMA, CSMA, ChMA) and acryl-modified polymers (e.g., F127DA). Polymerization is initiated by photoinitiator illumination to construct hydrogel materials with diverse physicochemical properties.
3. CMCMA can be used alone, undergoing polymerization and cross-linking upon illumination with a photoinitiator.
Preparation Method
1. Preparation of photoinitiator stock solution: Dissolve a specific mass of NAP or LAP to prepare a solution with a concentration in the range of 0.1 wt%-0.25 wt%, and store at 2-8 ℃ away from light.
2. Transfer the required mass of CMCMA into a centrifuge tube, then add the required volume of the photoinitiator stock solution to the tube.
3. Stir the sample at room temperature in the dark or shake it on a shaker until completely dissolved. If the sample clumps in the solution, first crush it with a spatula; if dissolution is slow, heat and stir at 50-60 ℃ to aid dissolution.
Precautions
1. The higher the labeling rate (degree of substitution) of CMCMA and the higher the prepared concentration, the greater the modulus of the cured gel and the shorter the curing time.
2. The higher the molecular weight of CMCMA, the better the toughness of the cured gel and the less prone it is to fracture.
3. The higher the molecular weight of CMCMA, the greater the viscosity of the prepared solution. For CMCMA with a molecular weight of 300 kDa, the recommended concentration does not exceed 3 wt%; for CMCMA with a molecular weight of 90 kDa, the recommended concentration does not exceed 6 wt%.
4. The higher the concentration of the photoinitiator stock solution, the faster the curing rate of the CMCMA solution and the more brittle the resulting cured gel.
Product Applications
1. Controlled drug release, bioprinting, tissue engineering organ construction, wound dressings, anti-adhesion barrier layers, etc.
2. Chondrocyte differentiation: Constructing cell-laden hydrogels to promote the re-differentiation of chondrocytes in vitro.
Sterilization Methods
1. Filtration sterilization (recommended): Sterilize the solution by filtration using a 0.22 μm sterile syringe filter. This method is only suitable for low-concentration solutions; for high-concentration solutions, use pasteurization or autoclaving.
2. Pasteurization: Heat the solution to 80 ℃ and hold for 30 min; then rapidly transfer it to an ice-water mixture to cool to room temperature. Repeat this process three times.
3. Autoclaving: Sterilize the solution in an autoclave at 121 ℃ for 8 min. After manual venting, rapidly transfer the solution to an ice-water mixture to cool to room temperature. Note that high temperatures can reduce gel performance, so strict adherence to the above steps is required when using this method.
Note: Sterile solutions can be stored temporarily at 2-8 ℃ away from light and are recommended for use within 7 days; non-sterile solutions can be stored temporarily at 2-8 ℃ away from light and are recommended for use within 48 hours.
Product Advantages
1. Batch Consistency: Standardized production processes are adopted to ensure high repeatability and controllability of CMCMA in composition, physicochemical properties and biological characteristics across different batches.
2. Ultra-High Purity: A unique production process is used to effectively remove small molecules of methacrylic acid and process impurities, achieving an ultra-low impurity level and ensuring the safety of CMCMA for biomedical applications.
3. Reliable Safety: Each batch of product is released only after strict standardized testing, guaranteeing the safety of CMCMA in biomedical applications.
4. High Stability: In accordance with the Guiding Principles for Stability Study of Non-Invasive Implantable Medical Devices, real-time stability and accelerated stability tests have verified that CMCMA maintains stable quality under the labeled storage conditions.
ZJ26F0434405
危险品化学品经营许可证（带存储）